We're pleased to recommend linzagolix as a new treatment option for endometriosis. As a once-daily tablet taken at home, it offers a convenient way for people with endometriosis to manage their ...

We know that AI is vital for the NHS to deliver reduced waiting times and faster diagnoses for patients, which is why the health service plays such a vital role in supporting technologies like DERM by ...

The evidence considered by NICE primarily focuses on diagnostic accuracy, clinical outcomes and the impact of the technology on the teledermatology pathway for urgent suspected skin cancer referral.

NICE has said that Deep Ensemble for Recognition of Malignancy (DERM, an artificial intelligence [AI] technology) can be used in teledermatology services in the NHS to assess and triage skin lesions ...

This topic was considered by NICE's diagnostics advisory committee, which is a standing advisory committee of NICE. Committee members are asked to declare any interests in the technologies to be ...

The company should work with providers and central NHS England teams to begin the research. Planning for a prespecified period for the set-up of the technology is advised. During this period, training ...

NICE's early value assessment on artificial intelligence (AI) technologies for assessing and triaging skin lesions recommends that Deep Ensemble for Recognition of Malignancy (DERM) can be used in the ...

This section describes the evidence gaps that need to be addressed for future committee decision making. The committee will not be able to make a positive recommendation without these being addressed.

Dear stakeholders, For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) ...